Deepak Bhatt, MD, MPH, reflects on the rapid ascent of sotagliflozin (Zynquista) into the spotlight of clinicians specializing in cardiometabolic health thanks to the success of the phase 3 SCORED and SOLOIST trials.
The revelations of the cardiorenal protective benefits of SGLT2 inhibitors has been one driven largely by agents like dapagliflozin and empagliflozin, a pair of trials examining the currently unapproved sotagliflozin have made massive contributions to the understanding of the class since results were published less than a year ago.
While they may not have been met with the same initial fanfare as trials within the DAPA or EMPA programs, the phase 3 SCORED and SOLOIST trials have provided a wealth of evidence detailing the effects of SGLT1/2 inhibition in patients with type 2 diabetes and heart failure or chronic kidney disease. While the trials demonstrate the safety and efficacy of sotagliflozin, investigators purport the results also offer insight into the effects of SGLT2 inhibition, such as appropriate timing of initial dosing related to hospitalization.
With initial results presented at AHA 2020, multiple subsequent meetings, including ACC 2021 and ADA 2021, the scientific community has been able to add to its current knowledge base in a way few could have predicted. To learn more about how the SCORED and SOLOIST have altered the understanding of SGLT2 inhibitor use in patients with type 2 diabetes, Practical Cardiology reached out to the trials’ principal investigator Deepak Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital.